Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Commentary: Calcium antagonist controversy, does the accusing finger also point to beta-blockers and methyldopa?

Journal of Human Hypertension volume 11, pages 201–204 (1997)Cite this article

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Medical Research Council, Heart Research Unit, University of Cape Town, Cape Town, South Africa

    LH Opie

Authors
  1. LH Opie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Opie, L. Commentary: Calcium antagonist controversy, does the accusing finger also point to beta-blockers and methyldopa?. J Hum Hypertens 11, 201–204 (1997). https://doi.org/10.1038/sj.jhh.1000418

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1000418

Keywords

  • calcium antagonists
  • mortality
  • case control
  • hypertension
  • methyldopa
  • beta-blockers

Search

Advanced search

Quick links